...
首页> 外文期刊>Investigative ophthalmology & visual science >In Vitro and In Vivo Sustained Zero-Order Delivery of Rapamycin (Sirolimus) From a Biodegradable Intraocular Device
【24h】

In Vitro and In Vivo Sustained Zero-Order Delivery of Rapamycin (Sirolimus) From a Biodegradable Intraocular Device

机译:雷帕霉素(西罗莫司)从生物可降解眼内装置的体外和体内持续零级递送。

获取原文
           

摘要

Purpose: We created implantable intraocular devices capable of constant and continuous rapamycin release on the scale of months to years. Methods: Polycaprolactone (PCL) thin films were used to encapsulate rapamycin to create implantable and biodegradable intraocular devices. Different film devices were studied by modifying the size, thickness, and porosity of the PCL films. Results: In vitro release of rapamycin was observed to be constant (zero-order) through 14 weeks of study. Release rates were tunable by altering PCL film porosity and thickness. In vivo release of rapamycin was observed out through 16 weeks with concentrations in the retinaa??choroid in the therapeutic range. Rapamycin concentration in the blood was below the lower limit of quantification. The drug remaining in the device was chemically stable in vitro and in vivo, and was sufficient to last for upwards of 2 years of total release. The mechanism of release is related to the dissolution kinetics of crystalline rapamycin. Conclusions: Microporous PCL thin film devices demonstrate good ocular compatibility and the ability to release rapamycin locally to the eye over the course of many weeks.
机译:目的:我们创建了可植入雷帕霉素的植入式眼内装置,能够持续数月至数年的雷帕霉素持续释放。方法:使用聚己内酯(PCL)薄膜封装雷帕霉素,制造可植入和可生物降解的眼内装置。通过改变PCL膜的尺寸,厚度和孔隙率,研究了不同的膜装置。结果:在研究的14周中,雷帕霉素的体外释放是恒定的(零级)。释放速率可通过改变PCL膜的孔隙率和厚度来调节。在整个16周内观察到雷帕霉素的体内释放,其中视网膜脉络膜中的浓度在治疗范围内。血液中雷帕霉素的浓度低于定量下限。保留在装置中的药物在体外和体内化学稳定,足以持续2年以上的总释放。释放机理与雷帕霉素结晶的溶解动力学有关。结论:微孔PCL薄膜装置显示出良好的眼部相容性,并具有在数周的过程中局部释放雷帕霉素的能力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号